303 related articles for article (PubMed ID: 28443349)
1. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
Witter DP; Holbert RC; Suryadevara U
Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
[TBL] [Abstract][Full Text] [Related]
2. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
4. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
5. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
Meyer JM
CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
9. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
10. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
12. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of tardive dyskinesia: Five steps to success.
Citrome L
J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
[TBL] [Abstract][Full Text] [Related]
17. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
Chan CH; Chan HY; Chen YC
Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
Nagano M; Susuta Y; Masui H; Watanabe Y; Watanabe K
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):107-116. PubMed ID: 38421921
[TBL] [Abstract][Full Text] [Related]
19. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
[No Abstract] [Full Text] [Related]
20. Pharmacological treatment of tardive dyskinesia: recent developments.
Caroff SN; Campbell EC; Carroll B
Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]